Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (10337)	1/20/2012 4:05:58 PM
From: Arthur Radley	2 Recommendations Respond to of 10345

Good news today: The U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy, or PML, in people using the drug Tysabri to treat multiple sclerosis or Crohn’s disease. The Stratify JCV Antibody ELISA test, when used with other clinical data from the patient, can help health care providers determine the risk for developing PML in MS and CD patients. The Stratify JCV Antibody ELISA test is manufactured by Focus Diagnostics. Tysabri is co-marketed by Biogen Idec (BIIB) and Elan Pharmaceuticals .